Vivoryon Therapeutics AG (0R3M) Ratios
Vivoryon Therapeutics AG Ratios
GB:0R3M's free cash flow for Q2 2026 was $-3.15M. For the 2026 fiscal year, GB:0R3M's free cash flow was increased by $0.00 and operating cash flow was $-3.15M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.68 | 7.20 | 9.37 | 9.40 | 4.00 |
| Quick Ratio | 7.68 | 7.20 | 9.37 | 9.40 | 4.00 |
| Cash Ratio | 6.71 | 6.69 | 5.83 | 8.13 | 2.90 |
| Solvency Ratio | -3.12 | -6.00 | -6.20 | -5.75 | -1.57 |
| Operating Cash Flow Ratio | -10.10 | -13.71 | -6.77 | -6.68 | -2.23 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -319.57 | -566.87 | -231.85 | -122.36 |
| Net Current Asset Value | $ 3.64M | $ 6.66M | $ 25.27M | $ 25.82M | $ 12.27M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 |
| Debt-to-Equity Ratio | 0.02 | 0.01 | 0.00 | 0.00 | 0.01 |
| Debt-to-Capital Ratio | 0.02 | 0.01 | 0.00 | 0.00 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.59 | 1.43 | 1.17 | 1.18 | 1.48 |
| Debt Service Coverage Ratio | -200.67 | -139.28 | -299.14 | -237.04 | -107.47 |
| Interest Coverage Ratio | -203.93 | -243.73 | -514.95 | -1213.83 | -533.58 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 |
| Net Debt to EBITDA | 0.61 | 0.46 | 0.65 | 0.94 | 1.20 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 85.50% | 0.00% | 83.89% |
| EBIT Margin | 0.00% | 0.00% | 787.85% | 0.00% | -113.33% |
| EBITDA Margin | 0.00% | 0.00% | 783.23% | 0.00% | -111.80% |
| Operating Profit Margin | 0.00% | 0.00% | 796.60% | 0.00% | -118.97% |
| Pretax Profit Margin | 0.00% | 0.00% | 789.39% | 0.00% | -113.55% |
| Net Profit Margin | 0.00% | 0.00% | 782.93% | 0.00% | -117.57% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 782.93% | 0.00% | -117.57% |
| Net Income Per EBT | 100.00% | 100.00% | 99.18% | 99.30% | 103.53% |
| EBT Per EBIT | 96.47% | 98.13% | 99.09% | 97.33% | 95.45% |
| Return on Assets (ROA) | -117.76% | -182.28% | -91.93% | -89.73% | -51.61% |
| Return on Equity (ROE) | -187.29% | -261.02% | -107.84% | -106.23% | -76.43% |
| Return on Capital Employed (ROCE) | -137.36% | -212.05% | -104.30% | -103.62% | -65.78% |
| Return on Invested Capital (ROIC) | -136.06% | -209.51% | -103.17% | -102.21% | -65.16% |
| Return on Tangible Assets | -131.72% | -197.41% | -94.83% | -91.17% | -52.76% |
| Earnings Yield | -23.10% | -39.70% | -13.81% | -12.39% | -3.33% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | -7.31 | 0.00 | 3.20 |
| Payables Turnover | 0.32 | 0.14 | -0.18 | 0.06 | 0.40 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | -47.63 | 0.00 | 37.77 |
| Asset Turnover | 0.00 | 0.00 | -0.12 | 0.00 | 0.44 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | -0.13 | 0.00 | 0.50 |
| Cash Conversion Cycle | -1137.21 | -2520.24 | 1962.11 | -5765.19 | -803.83 |
| Days of Sales Outstanding | 0.00 | 0.00 | -49.91 | 0.00 | 113.94 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1137.21 | 2520.24 | -2012.02 | 5765.19 | 917.76 |
| Operating Cycle | 0.00 | 0.00 | -49.91 | 0.00 | 113.94 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.31 | -0.74 | -0.85 | -0.99 | -0.56 |
| Free Cash Flow Per Share | -0.31 | -0.74 | -0.87 | -0.99 | -0.56 |
| Dividend Paid and CapEx Coverage Ratio | -1409.17 | -9587.00 | -41.91 | -1676.46 | -402.04 |
| Capital Expenditure Coverage Ratio | -1409.17 | -9587.00 | -41.91 | -1676.46 | -402.04 |
| Operating Cash Flow Coverage Ratio | -78.29 | -187.98 | -566.87 | -165.11 | -50.25 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 5.95 | 0.00 | -1.05 |
| Free Cash Flow Yield | -22.08% | -37.01% | -10.75% | -9.60% | -2.97% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.30 | -2.52 | -7.24 | -8.07 | -30.03 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | -56.69 | 0.00 | 35.30 |
| Price-to-Book (P/B) Ratio | 8.11 | 6.57 | 7.81 | 8.57 | 22.95 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.53 | -2.70 | -9.30 | -10.42 | -33.67 |
| Price-to-Operating Cash Flow Ratio | -4.53 | -2.70 | -9.53 | -10.43 | -33.76 |
| Price-to-Earnings Growth (PEG) Ratio | 0.07 | 0.09 | 0.58 | -0.08 | 1.25 |
| Enterprise Value Multiple | -3.63 | -2.09 | -6.58 | -7.13 | -30.38 |
| Enterprise Value | 32.81M | 42.55M | 186.69M | 200.82M | 365.56M |
| EV to EBITDA | -3.63 | -2.09 | -6.58 | -7.13 | -30.38 |
| EV to Sales | 0.00 | 0.00 | -51.57 | 0.00 | 33.96 |
| EV to Free Cash Flow | -3.88 | -2.22 | -8.46 | -9.21 | -32.39 |
| EV to Operating Cash Flow | -3.88 | -2.22 | -8.67 | -9.21 | -32.47 |
| Tangible Book Value Per Share | 0.15 | 0.27 | 1.00 | 1.18 | 0.80 |
| Shareholders’ Equity Per Share | 0.18 | 0.30 | 1.04 | 1.20 | 0.83 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.01 | 0.01 | -0.04 |
| Revenue Per Share | 0.00 | 0.00 | -0.14 | 0.00 | 0.54 |
| Net Income Per Share | -0.33 | -0.79 | -1.12 | -1.28 | -0.63 |
| Tax Burden | 1.00 | 1.00 | 0.99 | 0.99 | 1.04 |
| Interest Burden | 0.96 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | -4.87 | 0.00 | 1.62 |
| SG&A to Revenue | 0.00 | 0.00 | -0.90 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | -1.09 | 0.00 | 0.16 |
| Income Quality | 0.96 | 0.93 | 0.76 | 0.77 | 0.89 |
Currency in EUR